ArticleCureus2025
Exploring Serum Anti-thyroid Peroxidase Antibodies and High-Sensitivity C-reactive Protein as Inflammatory Markers in Subclinical Hypothyroidism: A Comprehensive Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Thyroid Peroxidase and its Gene Variants as Diagnostic Markers in Subclinical Hypothyroidism: Evidence from a Duhok Case-Control Study.Biochemical genetics · 2026Article
- Phenotypic Age Acceleration as a Mediator in Thyroid Hormone-Related Cardiovascular Risk Among the Elderly.Cardiology research and practice · 2026Article
- Autoimmune Thyroid Disease and Female Fertility: Does Anti-TPO Accelerate Ovarian Aging?Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim Subclinical hypothyroidism (SCH) is a biochemical condition defined by elevated thyroid-stimulating hormone (TSH) levels with normal free thyroxine (FT4) levels, often occurring without overt clinical symptoms. Emerging evidence suggests a role for autoimmune and inflammatory processes, with anti-thyroid peroxidase antibodies (anti-TPO) and high-sensitivity C-reactive protein (hsCRP) as potential markers of thyroid autoimmunity and systemic inflammation. This study evaluates the significance of these markers in SCH to elucidate their association with disease progression and clinical symptoms. This study aims to assess the roles of anti-TPO and hsCRP as inflammatory markers in SCH and to examine their correlations with clinical symptoms, lipid profiles, and cardiovascular risk, to stratify patients based on their autoimmune and inflammatory profiles. Methodology A retrospective, cross-sectional study was conducted on 220 patients, including 170 diagnosed with SCH and 50 euthyroid controls. Patients were categorized into SCH with anti-TPO positivity (SCH+), SCH without anti-TPO positivity (SCH-), and euthyroid controls. Serum TSH, FT4, anti-TPO, and hsCRP levels were analyzed using chemiluminescent immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and turbidimetric immunoassay. Statistical analyses, including Kruskal-Wallis and correlation tests, evaluated associations between hsCRP, anti-TPO, and clinical parameters. Results SCH+ participants demonstrated significantly higher levels of TSH (7.6 ± 2.1 mIU/L), hsCRP (4.2 ± 1.6 mg/L), and anti-TPO antibodies (116.5 ± 34.8 IU/mL) compared to SCH- and controls (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.